MDK and neoplasm: A recent study precisely looked into the effects of MDK within the HCC microenvironment and postulated MDK inhibition as valuable therapeutic addition to anti-PD-1 immunotherapy in HCC patients, as the standard treatment, sorafenib, leads to an immunosuppressive tumor microenvironment due to increased MDK expression (135).